Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| FATE | CLUSTER | bearish | 5/10 | Two insiders at Fate Therapeutics, including the CEO, sold a combined $204K worth of shares in open-market transactions | Aug 6, 2026 |
| PCVX | CLUSTER | neutral | 2/10 | Two top executives at Vaxcyte, the CEO and CFO, sold a combined $395K in open-market stock over a one-week window, with | Aug 6, 2026 |
| PFE | CLUSTER | neutral | 3/10 | Two Pfizer directors, Ronald Blaylock and Mortimer Buckley, made open-market purchases totaling ~$1.96M on August 5, 202 | Aug 6, 2026 |
| SYRE | CLUSTER | bearish | 5/10 | CEO Turtle Cameron and CFO Scott Burrows sold a combined $561K in open-market sales on August 3, 2026, with the CEO sell | Aug 5, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Three Arcutis insiders (Watanabe, Matsuda, Burnett) sold a total of $171K in open-market sales on August 3, 2026, at ~$2 | Aug 5, 2026 |
| ALMS | CLUSTER | neutral | 4/10 | Five C-suite insiders at Alumis (ALMS) sold a combined $326K in open-market sales on August 3, 2026, all at $26.37. The | Aug 5, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Two senior insiders at BeOne Medicines (CFO and SVP/General Counsel) sold a combined ~$700K in open-market sales within | Aug 5, 2026 |
| NRIX | CLUSTER | neutral | 3/10 | Three C-suite insiders at Nurix Therapeutics (NRIX) sold a total of $534K in open-market shares over a 7-day window, wit | Aug 5, 2026 |
| CAMP | CLUSTER | bullish | 8/10 | Five Camp4 Therapeutics insiders, including the CEO, CFO, CMO, a director, and the largest 10% owner (5AM Partners), mad | Aug 5, 2026 |
| CORT | CLUSTER | neutral | 3/10 | CFO Atabak Mokari and officer Sean Maduck sold a combined $3.29M in open-market sales within a week, with CFO Mokari exe | Aug 5, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three C-suite insiders at Nurix Therapeutics (CSO, CLO, CFO) sold a total of $461K in open-market shares over a 7-day wi | Aug 5, 2026 |
| INCY | CLUSTER | neutral | 3/10 | The CSO and President of R&D at Incyte sold a combined $2.16M in open-market shares in the week following the Q2 2026 ea | Aug 5, 2026 |
| XERS | CLUSTER | neutral | 2/10 | Two non-C-suite insiders at Xeris Biopharma sold a combined $254K in open-market transactions over a 7-day window. The t | Aug 4, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | CEO Derek Maetzold and CCO Tobin Juvenal sold a combined ~$286K in open-market sales over a 2-day window (July 31–Aug 3) | Aug 4, 2026 |
| NRIX | CLUSTER | neutral | 3/10 | Three C-suite insiders at Nurix Therapeutics (CFO, CSO, CLO) sold a total of ~$515K in open-market sales over a 7-day wi | Aug 4, 2026 |
| MPLT | CLUSTER | bullish | 7/10 | A mixed insider cluster at MapLight Therapeutics shows a 10% owner (Catalyst4, Inc.) making a $13M open-market purchase | Aug 4, 2026 |
| IQV | CLUSTER | neutral | 4/10 | Four IQVIA insiders sold a total of ~$14.8M in shares over a 7-day window ending 7/31/2026, including a large multi-leg | Aug 4, 2026 |
| RARE | CLUSTER | neutral | 2/10 | Two C-suite insiders at Ultragenyx (CFO and EVP/Chief Legal Officer) sold a combined $164K in open-market sales on Augus | Aug 4, 2026 |
| TRDA | CLUSTER | neutral | 4/10 | Two insiders at Entrada Therapeutics (Director Kush Parmar and 10% owner 5AM Ventures) sold a combined $1.59M in open-ma | Aug 3, 2026 |
| ALKS | CLUSTER | neutral | 2/10 | Two Alkermes executives (EVP CLO and EVP R&D/CMO) sold a combined $536K in open-market shares on August 3, 2026, one wee | Aug 3, 2026 |
| ALKS | CLUSTER | neutral | 3/10 | Two Alkermes insiders (EVP R&D/CMO and EVP/CLO) sold a combined $536K in open-market shares on August 3, 2026, one week | Aug 3, 2026 |
| PGEN | CLUSTER | neutral | 2/10 | Precigen insiders (CFO and COO) sold a combined $826K in open-market sales over a 4-day window. The CFO sold $606K at $6 | Aug 3, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three C-suite insiders at Nurix Therapeutics (NRIX) sold a combined $539K of stock in a 7-day window, representing only | Aug 3, 2026 |
| IQV | CLUSTER | neutral | 2/10 | CEO Ari Bousbib and CFO Eric Sherbet sold a combined $2.35M in open-market transactions on July 29, 2026, following IQVI | Aug 1, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | CEO Robert Blum and EVP/Chief Commercial Officer Andrew Callos sold a combined $1.72M in open-market shares over a 4-day | Jul 31, 2026 |
| PRTA | CLUSTER | neutral | 2/10 | Two C-suite insiders at Prothena (PRTA) sold a combined $136K in open-market sales on July 29, 2026, following tax-withh | Jul 30, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three C-suite insiders at Nurix Therapeutics (CFO, CSO, CLO) exercised stock options and immediately sold a combined ~$2 | Jul 30, 2026 |
| LQDA | CLUSTER | neutral | 3/10 | Two Liquidia Corp insiders, Director Stephen Bloch and Chief Business Officer Jason Adair, sold a combined $387K in open | Jul 29, 2026 |
| SCTX | CLUSTER | bullish | 8/10 | A massive insider buying cluster at Scribe Therapeutics: six insiders (including directors OrbiMed, Carl Gordon, and Beh | Jul 29, 2026 |
| MEDP | CLUSTER | neutral | 2/10 | CEO and EVP of Operations at Medpace sold a combined $6.61M in open-market sales over two days at ~$600/share. The CEO s | Jul 29, 2026 |